Merck & Co.
AWARDS
NEWS
Ginkgo Bioworks partnered with Merck on engineered enzymes for use as biocatalysts for Merck’s active pharmaceutical ingredient (API) manufacturing programs.
Top-line data from the Phase III STELLAR trial revealed that Merck’s activin receptor candidate sotatercept reached its primary endpoint in pulmonary arterial hypertension.
This week had a flurry of biopharma patent cases, from Novartis vs Gilenya, Merck vs Viatris, and Aligos vs Janssen, either filed or court decisions being made.
In honor of World Cancer Research Day, Sept. 24, BioSpace spoke with Elevation Oncology, Janssen, Merck and Teclison to learn more about the latest innovations in immuno-oncology.
The announcement follows a subgroup analysis of the Phase III SOLO3 trial which showed patients treated with Lynparza saw a 33% greater risk of death than controls who received standard chemotherapy.
Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
JOBS
IN THE PRESS